April 2022 Medical Image of the Month: COVID Pericarditis

Figure 1. A: Pericardial enhancement on thoracic CT (red arrows). B: Thoracic CT in lung windows showing mosaic attenuation (black arrows) and bilateral pleural effusions (red arrows).

Figure 2. A: Static image of parasternal short axis on transthoracic echocardiogram showing moderate, generalized pericardial effusion with right ventricular diastolic collapse (red arrow). B. Static image of parasternal long axis on transthoracic echocardiogram again showing a moderate, generalized pericardial effusion (red arrow). Lower panel: video of echocardiogram in parasternal long axis view.

A 76-year-old patient presented with fatigue and shortness of breath after missing one session of dialysis. Past medical history included end stage renal disease on hemodialysis and atrial fibrillation on anticoagulation. Initial labs showed that she was COVID positive with mild elevation in troponin and a BNP 1200. While an inpatient, she had received a few sessions of dialysis and treatment for COVID (including dexamethasone and remdesivir). Initial echo showed an ejection fraction of 60-65% with a small generalized pericardial effusion, a thickened pericardium with calcification. A few days after admission patient was suddenly noted to be hypotensive with systolic blood pressure in the 70s and altered mental status. Repeated labs showed a D-Dimer of 17,232, leukocytosis, lactic acidosis, troponin 0.556 ng/ml and arterial blood gas with metabolic acidosis. With a worsening clinical picture, repeat imaging was obtained. CT angiography of the chest was negative for pulmonary embolism; however, it showed a large pericardial effusion with reduced size of the right ventricle more so than left, concerning for cardiac tamponade (Figure 1A). CT chest also showed moderate-to-large pleural effusions with scattered mosaic attenuation of the lung parenchyma (Figure 1B). Repeat transthoracic echocardiogram had a moderate generalized pericardial effusion with right ventricular diastolic collapse concerning for pericardial tamponade (Figure 2). Her airway was secured with endotracheal intubation and vasopressors added for hemodynamic support. Pericardiocentesis was indicated however, patient’s INR was severely elevated in the setting of anticoagulation use. Efforts were made to lower INR with FFP; however, patient had a PEA arrest the following day and expired.

COVID-19 has been classically known for its detrimental lung damage; however, it has shown to cause extrapulmonary effects as well. Cardiac injury is one phenomenon that has been seen with the fulminant inflammatory state that COVID is known to cause. With a few cases reported for COVID pericarditis, it is a possible culprit when all other causes have been ruled out. Pericardial involvement can be seen in about 20% of COVID 19 cases, with effusion found in about 5% of patients (1). Concomitant myocarditis can also be found in up to 17% of patients. Having isolated cardiac involvement with COVID is rare, with most cases presenting mainly as lung involvement in addition to other organs affected as well. Clinically, patients with pericarditis typically experience chest pain and in the setting of COVID infection, an increase in inflammatory markers. Characteristic findings of pericarditis include friction rub on auscultation, diffuse ST elevations on EKG and a potential progression to pericardial effusion on echo. When a pericardial effusion becomes large enough, it can progress to cardiac tamponade (2). Having a high clinical suspicion for tamponade is crucial in a patient who has developed respiratory distress and hypotension in the setting of recent viral pericarditis. It is a clinical diagnosis and requires rapid treatment with pericardiocentesis to prevent cardiac arrest.

Sarah Youkhana, MD¹ and Maged Tanios, MD²

St. Mary Medical Center, Long Beach, CA USA

¹Internal Medicine Resident, PGY-3

²Medical Director, Critical Care Services

References

1. Diaz-Arocutipa C, Saucedo-Chinchay J, Imazio M. Pericarditis in patients with COVID-19: a systematic review. J Cardiovasc Med (Hagerstown). 2021 Sep 1;22(9):693-700. [CrossRef] [PubMed]
2. Imazio M, Gaita F, LeWinter M. Evaluation and Treatment of Pericarditis: A Systematic Review. JAMA. 2015 Oct 13;314(14):1498-506. [CrossRef] [PubMed]

Cite as: Youkhana S, Tanios M. April 2022 Medical Image of the Month: COVID Pericarditis. Southwest J Pulm Crit Care Sleep 2022;24(4):62-3. doi: https://doi.org/10.13175/swjpccs006-22 PDF

March 2022 Medical Image of the Month: Pulmonary Nodules in the Setting of Diffuse Idiopathic Pulmonary NeuroEndocrine Cell Hyperplasia (DIPNECH)

Figure 1. Unenhanced chest CT images in the axial plane show solid, non-calcified and well-circumscribed nodules in the right upper lobe (RUL) (A) and lingula (B).  The RUL nodule is FDG-avid on axial fused FDG PET-CT image (C) whereas the lingular nodule is not (D).

Figure 2. Unenhanced chest CT images in the axial plane reconstructed with maximum intensity projection (MIP, A) and minimum intensity projection (MinIP, B) techniques show multiple scattered solid pulmonary nodules (arrows) and pulmonary mosaicism consistent with air-trapping (circled). Axial fused images from a ⁶⁸GA-DOTATATE PET-CT demonstrate some activity in the RUL nodule (C) and more prominent uptake in the lingular nodule (D).

Figure 3.  Hematoxylin and Eosin stained low-power pathological image (A) demonstrates the lingular carcinoid tumor (*) as well as several carcinoid tumorlets (arrows) in the adjacent lung. A separate specimen of lung stained with synaptophysin demonstrates multiple tumorlets in the small sample. When taken in conjunction with imaging findings, pathology is in-keeping with a diagnosis of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH).

A 62-year-old woman presented to an outside hospital with chronic cough, prompting a chest x-ray (CXR). Findings further prompted unenhanced chest CT to evaluate possible pulmonary nodules. The CT demonstrated multiple scattered, solid and centrilobular pulmonary nodules, most of which were small but there were two >1 cm nodules, one in the right upper lobe (RUL) and a second in the lingula (Figure 1A,B). A subsequent FDG PET-CT was performed demonstrating increased metabolic activity in the RUL nodule with no activity in the lingular nodule (Figure 1C,D). Biopsy of the RUL nodule was consistent with a carcinoid. At this point the patient was referred to our center for further management. A repeat chest CT failed to demonstrate any significant change in the nodules. MIP and MinIP reconstructions from that examination demonstrate multiple small, solid pulmonary nodules (arrows) (Figure 2A), many of which were associated with air-trapping resulting in pulmonary mosaicism (circled) (Figure 2B). A ⁶⁸GA-DOTATATE PET-CT was performed, the results of which provide stark contrast to the FDG-PET in that the RUL nodule demonstrated modest uptake (Figure 2C), whereas the lingular nodule showed very prominent update (Figure 2D). The lingular nodule was resected, H & E-stained pathology image (Figure 3A) demonstrated a typical carcinoid (*) with multiple carcinoid tumorlets in the surgical specimen (arrows). A separate specimen stained with synaptophysin demonstrates multiple neuroendocrine tumorlets. Pathological findings, in conjunction with patient demographics and imaging findings, were consistent with Diffuse Idiopathic Pulmonary NeuroEndocrine Cell Hyperplasia (DIPNECH).

DIPNECH is recognized as a pre-neoplastic lesion in the 2015 WHO classification of lung tumors (1). There is neuroendocrine cell proliferation within the small bronchi and bronchioles which may progress beyond the basement membrane, forming carcinoid tumorlets and in some cases, eventually carcinoid tumors.  These airway-centered nodules cause obstruction.  In addition, there is often an association between DIPNECH and constrictive bronchiolitis, which causes further airway obstruction (2).  The vast majority of patients are women in their 50s-70s and most patients are symptomatic with the most common presenting symptoms being chronic cough and dyspnea (3,4).  Many of these patients are often mis-diagnosed with asthma initially (4).  The imaging findings of DIPNECH on CT are not specific but can be pathognomonic in some cases.  There are almost always innumerable small solid (and sometimes ground glass) centrilobular nodules and nodular bronchial thickening with associated pulmonary mosaicism related to air trapping.  Nodules are either stable or very slowly growing over years with the largest nodules usually being biopsied or resected and yielding typical carcinoid on pathology (4).  A relatively new nuclear medicine imaging study, 68Ga-DOTATATE PET-CT, shows promise as a higher resolution and more sensitive examination for detection of neuroendocrine tumors (relative to octreotide scans), including pulmonary carcinoid tumors in the setting of DIPNECH (5,6).

Clinton Jokerst MD¹, Henry Tazelaar², Carlos Rojas MD¹, Prasad Panse MD¹, Kris Cummings MD¹, Eric Jensen MD¹ and Michael Gotway MD¹

Departments of Radiology¹ and Pathology²

Mayo Clinic Arizona, Scottsdale, AZ USA

References

1. Gosney JR, Austin JHM, Jett J, et al. Diffuse pulmonary neuroendocrine cell hyperplasia. In: Travis WD, Brambilla E, Burke AP, et al., eds. WHO classification of tumours of the lung, pleura, thymus and heart. Lyon, IARC Press, 2015; pp. 78-79.
2. Samhouri BF, Azadeh N, Halfdanarson TR, Yi ES, Ryu JH. Constrictive bronchiolitis in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. ERJ Open Res. 2020 Nov 16;6(4):00527-2020. [CrossRef] [PubMed]
3. Rossi G, Cavazza A, Spagnolo P, Sverzellati N, Longo L, Jukna A, Montanari G, Carbonelli C, Vincenzi G, Bogina G, Franco R, Tiseo M, Cottin V, Colby TV. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome. Eur Respir J. 2016 Jun;47(6):1829-41. [CrossRef] [PubMed]
4. Little BP, Junn JC, Zheng KS, Sanchez FW, Henry TS, Veeraraghavan S, Berkowitz EA. Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: Imaging and Clinical Features of a Frequently Delayed Diagnosis. AJR Am J Roentgenol. 2020 Dec;215(6):1312-1320. [CrossRef] [PubMed]
5. Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, Delbeke D, Walker RC. 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. J Nucl Med. 2016 Jun;57(6):872-8. [CrossRef] [PubMed]
6. Fraum TJ, Ritter JH, Chen DL. Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia on Somatostatin Receptor Imaging. Am J Respir Crit Care Med. 2018 Nov 1;198(9):1223-1225. [CrossRef] [PubMed]

Cite as: Jokerst C, Tazelaar H, Rojas C, Panse P, Cummings K, Jensen E, Gotway M. March 2022 Medical Image of the Month: Pulmonary Nodules in the Setting of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH). Southwest J Pulm Crit Care Sleep;2022:40-42. doi: https://doi.org/10.13175/swjpccs010-22 PDF